Why the study?
Does oral sildenafil improve hemodynamics and exercise capacity in patients with nonoperable chronic thromboembolic pulmonary hypertension?
Does oral sildenafil improve hemodynamics and exercise capacity in patients with nonoperable chronic thromboembolic pulmonary hypertension?
Oral sildenafil significantly improves pulmonary hemodynamics and exercise capacity in patients with severe, nonoperable chronic thromboembolic pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; hypothesis-generating for sildenafil in nonoperable CTEPH.
Only a small percentage of patients with chronic thromboembolic pulmonary hypertension are eligible for pulmonary thrombendarterectomy. We investigated the effects of oral sildenafil on hemodynamics and exercise capacity in 12 nonoperable chronic thromboembolic pulmonary hypertension patients. All patients were in disease progression despite sufficient long-term anticoagulation and the best supportive care and suffered from severe pulmonary hypertension (pulmonary vascular resistance index 1,935 +/- 228 dyn. s. cm-5. m2, cardiac index 2.0 l. min-1. m-2, 6-minute walking distance 312 +/- 30 m). After approximately 6 months of sildenafil treatment, pulmonary hemodynamics and exercise capacity improved significantly (pulmonary vascular resistance index 1,361 +/- 177 L. min-1. m2, p = 0.004, cardiac index 2.4 +/- 0.2 L. min-1. m-2, p = 0.009, 6-minute walking distance 366 +/- 28 m, p = 0.02). Therefore, oral sildenafil may offer a new option for medical treatment of this devastating disease.
No takes yet. Share an insight, caveat, or question.
Ghofrani et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: